Torrid Holdings Shares Soar Following Earnings Report
Money

Torrid Holdings Shares Soar Following Earnings Report

authorBy JL Collins
DateMar 20, 2026
Read time2 min

Torrid Holdings Inc. saw a significant boost in its stock value, with shares climbing 20% to $1.50 in after-hours trading. This jump followed the release of the California-based plus-size apparel retailer's financial outcomes for the fourth quarter and the entire fiscal year 2025, which concluded on January 31st. Notably, the company’s adjusted earnings before interest, taxes, depreciation, and amortization for the full year exceeded the upper limit of its own projections.

A closer look at the financial details reveals a nuanced picture of the company’s performance. For fiscal year 2025, Torrid Holdings reported adjusted EBITDA of $63.6 million, surpassing expectations, while total net sales reached $1.0 billion. However, the company recorded a net loss of $7 million for the year, a contrast to the net income of $16.3 million reported in the previous year. The fourth quarter presented its own set of challenges, with net sales decreasing by 14.3% to $236.2 million compared to $275.6 million a year prior. Comparable sales also saw a 10% decline, and the gross margin contracted from 33.6% to 30.0%. The net loss for the fourth quarter expanded to $8.1 million, or $0.08 per share, compared to a loss of $3.0 million, or $0.03 per share, in the same period last year. Despite these figures, CEO Lisa Harper characterized 2025 as a “transformational year,” with early indicators for the first quarter suggesting that the company's strategic turnaround efforts are beginning to yield positive results. Torrid also provided fiscal year 2026 guidance, forecasting first-quarter net sales between $236 million and $244 million, and adjusted EBITDA ranging from $14 million to $18 million. For the full year, net sales are expected to be between $940 million and $960 million, with adjusted EBITDA projected at $65 million to $75 million, excluding potential tariff impacts.

Torrid Holdings currently holds a market capitalization of $124 million, with its stock trading near its 52-week low. The company's resilience in navigating a challenging market environment, as evidenced by exceeding its EBITDA targets and positive initial first-quarter trends, underscores its commitment to strategic realignment and operational efficiency. This ability to adapt and improve amidst adversity reflects a robust spirit of enterprise and a dedication to long-term growth, offering a hopeful outlook for its future trajectory.

More Articles
Milestone Pharmaceuticals Prepares for Q4 Report Amidst Analyst Forecasts
Milestone Pharmaceuticals is set to release its Q4 earnings report. Analysts predict a quarterly loss of 16 cents per share on revenues of $1.20 million. The company recently appointed David Sandoval as General Counsel and Chief Compliance Officer. This article details recent analyst ratings and price target adjustments for MIST stock.
By T. Harv EkerMar 20, 2026
Market Turbulence: Dow Plunges Amidst 'Extreme Fear' Index Readings
U.S. stocks experienced a downturn on Thursday, with the Dow Jones dropping over 200 points for the second consecutive day. The CNN Money Fear and Greed index remained in the 'Extreme Fear' zone, reflecting prevailing market anxiety. This article details the market performance, economic indicators, and the components of the Fear & Greed Index, providing a comprehensive overview of the financial landscape.
By Mr. Money MustacheMar 20, 2026
Friday's Stock Watch: FedEx, Planet Labs, and More
As US stock futures show an upward trend this Friday morning, investors are keenly observing several companies. FedEx, Planet Labs, and Scholastic Corp. have all reported impressive earnings, with BitFuFu Inc. and Xpeng Inc. also on the radar for their upcoming financial disclosures. This article highlights the key financial performances and market movements of these prominent stocks, offering a snapshot of today's potential market movers.
By Natalie PaceMar 20, 2026
Analysts Adjust BioLineRx Projections Ahead of Q4 Results
Leading Wall Street analysts have revised their outlook for BioLineRx (NASDAQ: BLRX) as the biotechnology firm prepares to announce its fourth-quarter earnings. The adjustments follow the company's Q3 report, which showed increased losses and a significant decline in sales compared to the previous year. Investors are keenly watching the upcoming announcement for insights into the company's financial health and future prospects.
By Dave RamseyMar 20, 2026
Cryptocurrency Markets Show Mixed Signals Amid Geopolitical Tensions: Bitcoin Holds Steady, Ethereum Dips
Leading cryptocurrencies experienced varied performances as global markets reacted to a developing Middle East oil crisis. While Bitcoin maintained stability, Ethereum saw a slight decline. An analyst suggests Bitcoin is nearing a crucial support level that could trigger its next bull market cycle.
By Chika UwazieMar 20, 2026